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A liquid chromatography-mass spectrometry (LC-MS) method was developed and validated for the determination of therapeutic
levels of caffeine in dried blood spot (DBS) samples. Caffeine is used in the treatment of Apnoea of Prematurity (AoP) in newborn
children. Calibration DBS samples were prepared by spotting 15 µL of whole blood spiked with the analyte onto specimen
collection cards. 3 mm disks cut from the centre of the DBS were extracted in methanol containing the internal standard. The
extract was separated using a Zorbax Eclipse Plus C18 column and the MS, operated in electrospray positive ion mode, used
single ion monitoring at m/z 195 for caffeine and m/z 198 for the IS. The overall extraction recovery of caffeine from spiked blood
spots was demonstrated to be 44–47%. Validation of the microanalytical method showed good precision (coefficient of variation)
and accuracy (relative error) and specificity and was linear within the tested calibration range 500–25000 ng/mL for caffeine.
Investigation of different specimen collection papers revealed different matrix effects with significant ion suppression from the
FTA Elute paper itself. Requiring only a microvolume (15 µL) blood sample for analysis, the developed DBS based microanalytical
method has the potential to facilitate the routine monitoring of caffeine in neonates.
1. Introduction
The analysis of dried blood spots (DBS) is used routinely for
newborn screening where the low volume blood sample is
obtained from a simple heel prick procedure [1]. Advances
in instrumental techniques [2] have enabled the analysis of
DBS samples to be expanded to include therapeutic drug
monitoring [3, 4], paediatric pharmacokinetic (PK) studies
[5–8], and metabolite identification investigations [9, 10]. In
this investigation a DBS analytical approach is developed for
the routine monitoring of caffeine, used to treat Apnea of
Prematurity (AoP) in neonates, that is, children less than
1 month old. Despite there being many references in the
literature to the analysis of caffeine in blood, plasma, urine,
and saliva there are only two citing the determination
of caffeine in dried blood spots (DBS). The GC analysis
reported by Brazier et al. [11] required solvent extraction
followed by derivatisation with methyxanthine prior to
measurement. More recently a DBS method without the need
for several work-up steps and compound derivatisation has
been established [12]. This method, based on LC-MS/MS
analysis, has a lower limit of quantification (LLOQ) of
250 ng/mL based on a 15 µL DBS sample.
The aim of this investigation was to develop and validate
a caffeine DBS method using a simple LC-MS instrument.
The International guidelines [13, 14] on bioanalytical vali-
dation provide guidance on the range of tests to be carried
out and the criteria which developed methods must meet
to be considered suitable for drug monitoring in patients.
A working liquid chromatography-mass spectrometry (LC-
MS) with selected ion monitoring (SIM) method for the
quantification of caffeine was established and subjected to an
assessment of accuracy, precision, selectivity, sensitivity, and
matrix effect in line with these requirements.
2. Experimental
The methodology and validation results from investigations
of caffeine DBS quantification by LC-MS are presented in this
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section. All the research carried out was approved by the De
Montfort University ethical committee.
2.1. Chemicals and Materials. Caffeine (1,3,7-trimethylxan-
thine) ≥ 99.0% (HPLC) and the internal standard (IS)
caffeine-trimethyl-13C3 1 mg/mL 99% were obtained from
Sigma-Aldrich (Poole, UK). FTA Elute paper and Harris
punch and cutting mat were purchased from Whatman, UK
(Part of GE Healthcare). Blood collection tubes (containing
EDTA) and EDTA coated capillary tubes were obtained from
Sarstedt (Leicester, UK). HPLC grade water, acetonitrile,
and methanol and formic acid ≥98% were obtained from
Fisher Scientific (Loughborough, UK). Autosampler vials
with 0.3 mL inserts, eppendorf cups, and volumetric pipettes
(Eppendorf Research) were obtained from Fisher Scientific
(Loughborough, UK). The vortex (TopMix Wizard X),
shaker (IKA VXR Vibrax), and weighing scales (Mettler
Toledo XS105) were obtained from Fisher Scientific (Lough-
borough, UK). Specimen collection filter paper S&S 903
was obtained from Fisher Scientific (Loughborough, UK).
Filter paper Ahlstrom 226 was supplied by ID Biological
systems (South Carolina, USA). Sample glass tubes and
polythene bags for storage of blood spot specimens were
obtained from Richardson’s of Leicester (Leicester, UK) and
desiccant sachets were supplied by Sud-Chemie (Northwich,
UK). Blank blood (EDTA) for method validation and patient
sample analysis was obtained from healthy adult volunteers
asked to abstain from dietary sources of caffeine for at least
two weeks.
2.2. Preparation of Caffeine Stock and Working Solutions.
A stock solution of caffeine was prepared by dissolving
0.05 g in 5 mL of methanol : water (80 : 20, v/v) to pro-
duce a 10 mg/mL concentration. This was diluted with
methanol : water (50 : 50, v/v) to produce a 1000 µg/mL
working solution which was then used to make a spiking
solution for each calibration level. The final concentrations
of spiking solutions were 5.25, 10.5, 21, 105, 168, 315, 420,
and 525 µg/mL.
2.3. Preparation of Calibration and Calibration of Dried Blood
Spots. Blood samples with known concentrations of caffeine
were prepared by diluting 25 µL of each spiking solution with
500 µL of blank human whole blood. The final concentration
of the blood calibration standards were 250, 500, 1000, 5000,
8000, 15000, 20000, and 25000 ng/mL.
2.4. Extraction of Dried Blood Spots. Calibration and val-
idation blood spot standards were prepared by pipetting
15 µL volumes of spiked blood onto FTA Elute paper. These
were left to dry at room temperature overnight and were
then stored at room temperature in sealed plastic bags with
desiccant.
The dried blood spot extraction solution was prepared as
above to provide a 1000 µg/mL concentration of the caffeine-
trimethyl13 C3 (IS) which was then diluted with methanol to
produce a final concentration of 500 ng/mL.
The extraction procedure used to recover caffeine was as
follows.
(i) A 3 mm disc was punched out from the centre of DBS
samples and transferred to a tube to which 100 µL of
methanol containing 500 ng/mL of IS was added.
(ii) The tubes contents were mixed using a vortex and
extraction was facilitated by gentle shaking for 60
minutes.
(iii) Extracts were transferred to a clean tube and vortexed
briefly prior to LC-MS analysis.
2.5. LC-MS Sample Analysis. Samples were analysed using
an Agilent 1200 LCMS system operated in the positive ion
electrospray mode with selected ion monitoring (SIM) of the
[M+H]+ peaks of caffeine and the internal standard.
The chromatographic system consisted of an Agilent
1100 series quaternary solvent delivery pump, autosampler,
and vacuum degasser. Caffeine was analysed on a Zorbax
Eclipse Plus C18 column (150 mm × 2.1 mm i.d., 3.5 µm)
with a C18 guard column (Phenomenex, Macclesfield UK,
3.0 × 4.0 mm) under isocratic conditions. Mobile phases A
(water with 0.13% formic acid) and B (100% acetonitrile)
were held at 18% and 82%, respectively, over a run time of
5 minutes. The column oven temperature was set to 40◦C
and the flow rate was 200 µL/min. The injection volume was
10 µL.
MS detection was performed with an Agilent 1200 mass
spectrometer with a positive ESI source. The system was
calibrated on a daily basis using a tuning mixture supplied
by Agilent Technologies. The ionisation source settings
optimised to give maximum caffeine signal intensity were
as follows: fragmentor voltage, 95 V; drying temperature,
300◦C; capillary voltage, 3000 V; nebuliser pressure, 25 psig;
nitrogen gas flow, 7 L/min. The protonated molecular ion
[M+H]+ of caffeine at m/z 195 and IS at m/z 198 was
monitored using SIM mode. A dwell time of 289 msec was
used for each ion. The software programme Chemstation
(series B.1.3, Agilent Technologies) was used to operate the
system and acquire all data. Microsoft Excel 2007 (Microsoft
Corporation, USA) and Chemstation were used to analyse
the data.
2.6. Validation Procedures
2.6.1. Selectivity. To demonstrate the selectivity of the LC-
MS method, blank blood spots and caffeine spiked blood
spots were analysed and subsequently processed. Represen-
tative extracted ion chromatograms from the LC-MS data
at m/z 195 and m/z 198 were generated to show that other
components that could be present in the sample matrix or
from the sampling paper were not interfering with the signal
from the target analyte.
2.6.2. Linearity and Sensitivity. Caffeine calibration stan-
dards were prepared in replicate (n = 5) and analysed on
three separate days. A calibration plot of analyte/IS peak area
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(c) EIC m/z 198
Figure 1: A representative LC-MS chromatogram of a blank DBS sample extracted with IS where (a) is the total ion chromatogram (TIC),
(b) is the extracted ion chromatogram (EIC) for m/z 195, and (c) is the EIC for m/z 198.
and an equally weighted linear regression was applied. The
quantification limits of caffeine in the DBS extracts were
determined. The limit of quantification was based on a
signal-to-noise ratio of 10 in a 0.5 min window around the
elution time of the analyte in an analytical blank.
2.6.3. Accuracy and Precision. The assay accuracy and preci-
sion was assessed by analysing a calibration with 7 concen-
tration levels (n = 5) in triplicate on three separate days.
2.6.4. Matrix Effects. The matrix effect is a general term used
to describe factors which affect the ionization efficiency of a
compound in an electrospray source following the extraction
of a biological fluid with an organic solvent. Phospholipids
have been identified as an important endogenous source of
matrix effects and are present in different amounts in various
biological fluids including blood, plasma, and urine [15, 16].
The effect of the matrix on the resulting caffeine LC-MS
signal intensity was investigated at concentrations of 500 and
25000 ng/mL in replicate (n = 5). An assessment was made
by comparing the peak area of caffeine spiked into blank
DBS extracts with that of caffeine in solvent. A 90 µL volume
of blank DBS extract or 100% pure methanol was added
to 10 µL of caffeine spiking solution. The matrix effect was
calculated using peak area by the following equation:
Matrix effect % = Response in DBS extract
Response in pure solvent
× 100. (1)
2.6.5. Recovery of Caffeine from Dried Blood Spots. The
overall efficiency of the extraction method utilising 100%
methanol was investigated at DBS concentrations of 500,
8000, and 25000 ng/mL. At each concentration level replicate
(n = 5) 15 µL spots were made and allowed to dry. The
entire DBS was subsequently punched out and extracted with
100% methanol. Recovery was determined by comparing
the peak area obtained with DBS extracts to those obtained
from caffeine in solvent containing an amount which
assumes 100% recovery. Recoveries were calculated from the
following equation:
Recovery % = Response in DBS extract
Response in pure solvent
× 100. (2)
2.6.6. Stability Considerations. The room temperature stabil-
ity of caffeine solutions was investigated in replicate (n = 5)
using the 500 ng/mL caffeine spiking solution. The peak area
obtained from a freshly prepared solution was compared to
that from a solution which had been stored for 48 hours.
Caffeine stability in DBS samples was determined by
comparing the data from spots containing 1000 ng/mL and
20000 ng/mL, after 6 days storage at room temperature, with
the data obtained from freshly prepared DBS samples. The
spots were stored in a sealed plastic bag with a desiccant.
3. Results and Discussion
3.1. Selectivity. Under the chromatographic conditions a run
time of 5 minutes was achieved with coelution of caffeine
and IS at a retention time of 3.3 minutes. Method selectivity
was demonstrated following the analysis of DBS samples
collected from two individual human subjects. There were
no significant (≥20% of LLOQ peak area) interferences
observed in any of these chromatograms at the retention time
of analyte and IS. The selectivity of the method is shown
in the representative chromatograms, Figures 1 and 2. The
LC-MS trace (Figure 1) obtained from the extract of a blank
DBS sample shows the absence of any interfering peak at the
retention time for caffeine. The baseline lift off is a result
of the very low signal level recorded. The data obtained for
4 ISRN Chromatography
(Min)































1 2 3 4

















1 2 3 4
(c) EIC m/z 198
Figure 2: A representative LC-MS chromatogram of a spiked DBS at 500 ng/mL extracted with IS where (a) is the TIC, (b) is the EIC for m/z





















Compound no. 1, MSD1 TIC
Rel. res% (5): 9.0159e − 1
Area = 0.00005894∗ Amt + 0
Figure 3: Calibration plot of caffeine concentration against mean
(n = 5) analyte to IS peak area.
a spiked 500 ng/mL sample are shown in Figure 2. Signal-to-
noise ratios were calculated by dividing peak height by the
baseline noise (where noise is given as six times the standard
deviation of the linear regression).
3.2. Linearity and Sensitivity. A calibration plot of caffeine
concentration against analyte/IS peak area ratio showed that
the response was linear (r2 ≥ 0.99) over the calibration
concentration range of 500 to 25000 ng/mL (Figure 3). The
lower limit of quantification LLOQ with a signal-to-noise
ratio of ≥10 and CV% and RE% less than 20% was
determined to be 500 ng/mL.
3.3. Accuracy and Precision. The assay accuracy and precision
was assessed by analysing a calibration with 7 concentration
levels (n = 5) in triplicate on three separate days. Intraday
CV% and RE% was within the acceptable 20% limit at
the LLOQ and within 15% for all other concentrations.
In addition, the interday CV% and RE% was within 15%
(Table 1).
3.4. Matrix Effect. Initial results indicated substantial ion
suppression (≥15%) at both concentrations. Clark et al.
[17]. showed that FTA Elute papers produced the most
marked matrix effects and therefore comparisons were made
using S&S 903 filter paper. Extracts of both papers using
100% methanol were spiked with caffeine and were then
compared with similar caffeine concentration solutions in
100% methanol. Figure 4 shows the extent of the matrix
effect observed under each of the experimental conditions.
Components within extracts of blank DBS samples on FTA
Elute paper resulted in 32 and 40% ionisation suppression
of the caffeine signal under ESI at 500 and 25000 ng/mL,
respectively. Results from the FTA Elute paper showed a
similar matrix effect on the caffeine signal suggesting that
chemical components within FTA Elute paper rather than
endogenous components in blood are responsible for the ion
suppression. Under identical chromatographic conditions
using paper S&S 903 no significant matrix effects were
observed. This provided further evidence of matrix effects
arising from the impregnated chemicals in FTA Elute paper.
These results are in agreement with the findings of a study
of three different paper types (FTA Elute, FTA, and Ahlstrom
226) where despite the severity of the matrix effect observed
for some compounds, FTA Elute was found to be the only
paper that enablled an acceptable degree of accuracy and
precision for greater than 80% of test compounds [17]. On
that basis the authors concluded that FTA Elute was the
preferred choice of paper substrate for method development.
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Table 1: Intraday and interday accuracy (RE%) and precision (CV%) results for the LC-MS caffeine DBS method n = 5.
Nominal conc. (ng/mL)
Intraday
500 1000 5000 8000 15000 20000 25000
run 1
Mean conc. (ng/mL) 441.8 1034.2 5346.7 8325.0 15138.9 20061.8 24087.7
SD 75.0 20.2 698.2 339.6 668.4 1668.9 140.1
RE% −11.8 3.2 6.8 3.9 0.8 0.1 −3.8
CV% 17.0 2.0 13.1 4.1 4.4 8.3 4.7
run 2
Mean conc. (ng/mL) 562.0 1113.4 5237.2 7820.4 15204.0 17404.8 21902.6
SD 38.3 92.9 182.4 202.2 2112.4 604.3 1519.3
RE% 12.4 11.3 4.7 −2.2 1.4 −13.0 −12.4
CV% 6.8 8.3 3.5 2.6 13.9 3.5 6.9
run 3
Mean conc. (ng/mL) 503.6 971.5 4970.3 7387.8 15702.9 21355.2 24908.2
SD 60.1 38.9 341.1 318.0 1466.4 1766.7 2160.4
RE% 0.7 −2.8 −0.6 −7.7 4.7 6.8 −0.4
CV% 12.4 4.0 6.9 4.3 9.3 8.3 8.7
Interday
Mean conc. (ng/mL) 502.4 1039.7 5184.7 7844.4 15348.6 19607.3 23632.8
SD 75.1 77.6 456.9 469.6 1485.7 2165.5 2070.2
Average RE% 0.4 3.9 3.6 −2.0 2.3 −2.0 −5.5









































Figure 4: Matrix effect observed for caffeine at two concentrations
in FTA Elute DBS extract, FTA Elute paper extract, 903 paper
DBS extract, and FTA Elute DBS extract containing IS. Results are
presented as a percentage of the peak area observed in pure solvent
n = 5.
Several approaches have been used to remove matrix
effects including improved sample clean-up [18] or the use
of a labeled IS to compensate for the matrix effect [19].
The inclusion of the IS [19] was used to compensate for
this problem and the matrix effect % was calculated using
the analyte/IS peak area ratio. After the inclusion of IS the
observed matrix effect was within the accepted limit of 15%
at both concentrations.




Recovery (%) 47.0 44.2 44.9
SD 7.4 2.3 3.0
Precision (CV%) 15.6 5.2 6.6
3.5. Recovery of Caffeine from DBS Samples. The overall
efficiency of the extraction method utilising 100% methanol
was investigated at DBS concentrations of 500, 8000, and
25000 ng/mL. The overall recovery was relatively low (44 to
47%) but consistent and reproducible across the calibration
range of the assay (Table 2).
3.6. Stability. The variation in the peak areas from the
caffeine stock solutions was found to be 2.8% (CV, 1.3%).
Indicating stability of the solutions stored at room tempera-
ture for 48 hours.
Caffeine was shown (Table 3) to be stable on FTA elute
paper with the differences in data between stored and fresh
samples being less than 15%.
3.7. Carryover. Sample carryover was assessed by analysing
blank DBS extracts following the analysis of the highest
DBS concentration (25000 ng/mL) in the calibration range.
No significant peak (>20% of LLOQ peak area) was
observed in blank DBS chromatograms. Similarly, potential
contamination resulting from the punch was assessed by
analysing two blank DBS discs cut from the same punching
device previously used to cut out 10 discs of blood from
25000 ng/mL DBS samples. In the absence of a significant
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Table 3: Stability data for caffeine in DBS samples collected on FTA




Fresh Stored Fresh Stored
Mean conc. (ng/mL) 955 1034 18377 20054
SD 99 95 819 1057
CV% 10.3 9.2 4.5 5.3
% Difference +8.3 +9.1
peak attributable to caffeine in resulting chromatograms the
punching device was also excluded as a major factor affecting
assay accuracy and precision.
4. Conclusions
The accuracy (RE%) and precision (CV%) results for the
developed LC-MS method were within the accepted valida-
tion criteria of less than 20% at the LLOQ and less than
15% at all other tested concentrations. A linear response was
observed up to a DBS concentration of 25000 ng/mL with a
mean r2 = 0.9960. Reports by Lee et al. [20, 21] suggest that
during the treatment of AoP, the lowest anticipated caffeine
concentration is ∼2500 ng/mL and therefore an LLOQ of
500 ng/mL is more than adequate.
There were no significant interferences at the retention
time of caffeine and IS in any of the control DBS chro-
matograms or in samples collected from two adult volunteers
demonstrating the selectivity of the developed analytical
techniques. The results obtained here indicate the potential
of LC-MS (SIM) to provide a selective method for the
quantification of caffeine within DBS samples under the
sample preparation conditions used. Results from the matrix
effect experiment suggested significant ion suppression from
the FTA Elute paper itself and demonstrate the importance
of understanding the source and extent of the matrix effects.
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